Document is current

Article History

Received: 29 November 2021

Accepted: 25 January 2022

First Online: 26 March 2022

Declarations

:

: MF Yuen is an advisory board member and/or received research funding from AbbVie, Arbutus Biopharma, Assembly Biosciences, Bristol Myer Squibb, Dicerna Pharmaceuticals, GlaxoSmithKline, Gilead Sciences, Janssen, Merck Sharp and Dohme, Clear B Therapeutics, Springbank Pharmaceuticals; and received research funding from Arrowhead Pharmaceuticals, Fujirebio Incorporation and Sysmex Corporation. WK Seto received speaker’s fees from AstraZeneca and Mylan, is an advisory board member of CSL Behring, is an advisory board member and received speaker’s fees from AbbVie, and is an advisory board member, received speaker’s fees and researching funding from Gilead Sciences. The other authors have no conflict of interests.

: This article does not contain any studies with animals.

: All procedures were in accordance with the ethical standards of the responsible committee on human experimentation (institutional and national) and with the Helsinki Declaration of 1975, as revised in 2008. Informed consent was obtained from all patients for being included in the study.

: Informed consent was obtained from all individual participants included in this study. No identifiable personal data from recruited patients were included in this article.

: Not applicable.

: This study was registered and approved by the Institutional Review Board, University of Hong Kong/ Hospital Authority West Cluster; and the Research Ethics Committee, Hong Kong Sanatorium and Hospital.